Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Vincenzovegaon Sep 01, 2021 11:58am
238 Views
Post# 33794515

Selling Price

Selling PriceIf we get approval and first of its kind, better than all the rest of tests out there...
I hope we sell high right off the bat. I dont make sense to sell cheap. Awhlie back Rob did mention $30 a device to start off, I hope were not selling cheaper than that, considering the tests out there are way above $100 per test.

Plus no one even mentions their Antiboday test kits? Add that to the Venowave revenue.

Hopefully after approval, immediately followed by contracts we see a nice spike. Plus, if they remove the swab tests (PCR i believe) by the new year and were one of the company still standing, I might be dreaming, but why not $25 a share
<< Previous
Bullboard Posts
Next >>